The Language Educator and Globalization: How Do We Best Prepare Our Learners?

What Do We Know, How Do We Know It, and How Can We Best Apply It?

Adequate Nutrition May get You Home: Effect of Caloric/Protein Deficits on the Discharge Destination of Critically Ill Surgical Patients 37 D. Dante Yeh, MD; Eva Fuentes, MD; Sadeq A. Quraishi, MD, MHA, MMScH; Catrina Cropano, MSc; Haytham Kaafarani, MD, MPH; Jarone Lee, MD, MPH; David R. King, MD; Marc DeMoya, MD; Peter Fagenholz, MD; Kathryn Butler, MD; Yuchiao Chang, PhD; and George Velmahos...

P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients?

Thrombosis and Haemostasis 108.2/2012 The development of oral inhibitors of the platelet P2Y12 receptor has improved outcomes in patients with acute coronary syndromes (ACS) and in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) with stenting. The first thienopyridine drug, ticlopidine, proved to be effective after coronary stenting, but because of many...

How do we know the value of our research?

R esearch is vital to the progress of medicine. Patients depend on it to generate new knowledge that may improve their lives. Clinicians yearn for more effective tools and better guidance for themselves and their patients. Funders seek a substantial return on their investment, often in the form of a contribution to society. Researchers want their work to result in meaningful benefits for others...

How do we find the best biomarkers for cardiovascular disease?

Conventional cardiovascular risk assessment is based on traditional risk factors such as serum cholesterol concentrations (cholesterol, HDL cholesterol, LDL cholesterol) and blood pressure levels. It is becoming increasingly clear that the newer laboratory measures may help to refine risk estimates in the general population. In a recent publication of the MONICA (Monitoring of Trends and Determ...

Leadership to transform practice: how do we wear our words?